Make Informed Investment Decisions with Affordable Access to Experts
Looking at Evolus' DWP-450 (PrabotulinumtoxinA) purified botulinum toxin in treating glabellar (frown) linesTicker(s): EOLS, RVNC, AGN
Name: Dr Katie Beleznay - MD
Institution: UBC and Carruthers & Humphrey Cosmetic Medicine
- Clinical Instructor with the University of British Columbia Department of Dermatology; board certified dermatologist in both Canada and the United States and is fellowship trained in laser and cosmetic dermatology.
- Treats 5-15 patients a day 4 days a week with Botox.
- Sub-investigator for the BELMONT Phase 2 trial of DaxibotulinumtoxinA Injectable (RT002).
Please describe your clinical practice; roughly how many patients do you currently treat with injectables for glabellar lines?Added By: c_admin
What are your initial thoughts on DWP-450 (PrabotulinumtoxinA)? If approved how likely would you be to switch patients off Botox?Added By: c_admin
On a scale from 1-10, 10 being extremely excited, where would you rate your level of excitement for this drug?Added By: c_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.